Class information for:
Level 1: OREGOVOMAB//AFLIBERCEPT//GI PERFORATION

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
15300 650 45.1 84%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
222 19941 LYMPHANGIOGENESIS//ANGIOGENESIS//ENDOSTATIN

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 OREGOVOMAB Author keyword 11 78% 1% 7
2 AFLIBERCEPT Author keyword 4 16% 4% 23
3 GI PERFORATION Author keyword 3 60% 0% 3
4 POLY ADP RIBOSE POLYMERASE INHIBITORS Author keyword 2 44% 1% 4
5 RECURRENT OVARIAN CANCER Author keyword 2 11% 3% 20
6 INVEST THER EUT ONCOL HEMATOL Address 2 67% 0% 2
7 NHS ONCOL Address 2 67% 0% 2
8 VEGF TRAP Author keyword 2 21% 1% 9
9 PRIMARY PERITONEAL CANCER Author keyword 1 17% 1% 8
10 GYNECOL MED ONCOL EXPT THER EUT Address 1 100% 0% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 OREGOVOMAB 11 78% 1% 7 Search OREGOVOMAB Search OREGOVOMAB
2 AFLIBERCEPT 4 16% 4% 23 Search AFLIBERCEPT Search AFLIBERCEPT
3 GI PERFORATION 3 60% 0% 3 Search GI+PERFORATION Search GI+PERFORATION
4 POLY ADP RIBOSE POLYMERASE INHIBITORS 2 44% 1% 4 Search POLY+ADP+RIBOSE+POLYMERASE+INHIBITORS Search POLY+ADP+RIBOSE+POLYMERASE+INHIBITORS
5 RECURRENT OVARIAN CANCER 2 11% 3% 20 Search RECURRENT+OVARIAN+CANCER Search RECURRENT+OVARIAN+CANCER
6 VEGF TRAP 2 21% 1% 9 Search VEGF+TRAP Search VEGF+TRAP
7 PRIMARY PERITONEAL CANCER 1 17% 1% 8 Search PRIMARY+PERITONEAL+CANCER Search PRIMARY+PERITONEAL+CANCER
8 FALLOPIAN TUBE CANCER 1 12% 1% 8 Search FALLOPIAN+TUBE+CANCER Search FALLOPIAN+TUBE+CANCER
9 RECURRENT EPITHELIAL OVARIAN CANCER 1 27% 0% 3 Search RECURRENT+EPITHELIAL+OVARIAN+CANCER Search RECURRENT+EPITHELIAL+OVARIAN+CANCER
10 GASTROINTESTINAL PERFORATION 1 10% 1% 8 Search GASTROINTESTINAL+PERFORATION Search GASTROINTESTINAL+PERFORATION

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 FALLOPIAN TUBE CANCER 66 70% 8% 55
2 PRIMARY PERITONEAL 51 58% 9% 59
3 INTRAVENOUS AFLIBERCEPT 27 92% 2% 11
4 RECURRENT EPITHELIAL OVARIAN 21 39% 7% 43
5 PRIMARY PERITONEAL CARCINOMA 17 37% 6% 37
6 PHASE II CONSORTIA 17 72% 2% 13
7 EPITHELIAL OVARIAN 15 18% 12% 78
8 BEVACIZUMAB COMBINATION THERAPY 15 88% 1% 7
9 RECURRENT OVARIAN 13 33% 5% 33
10 SYMPTOMATIC MALIGNANT ASCITES 10 63% 2% 10

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target? 2015 3 68 29%
Targeted anti-vascular therapies for ovarian cancer: current evidence 2013 27 49 43%
The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis 2013 19 48 56%
Beyond chemotherapy: targeted therapies in ovarian cancer 2009 190 126 30%
New ways to successfully target tumor vasculature in ovarian cancer 2015 1 62 47%
Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer 2013 16 66 56%
Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer 2012 24 26 77%
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-Mechanistics, review of phase III randomized clinical trials, and regulatory implications 2014 12 51 35%
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review 2014 5 34 62%
Bevacizumab and ovarian cancer 2013 7 43 56%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 INVEST THER EUT ONCOL HEMATOL 2 67% 0.3% 2
2 NHS ONCOL 2 67% 0.3% 2
3 GYNECOL MED ONCOL EXPT THER EUT 1 100% 0.3% 2
4 HLTH HOSP CLIN 1 100% 0.3% 2
5 CHAIR OBSTET SURG GYNECOL 1 40% 0.3% 2
6 OXFORD GYNAECOL ONCOL 1 40% 0.3% 2
7 ASSOCIATES WOMENS HLTH 1 50% 0.2% 1
8 EPFL QUARTIER INNOVAT 1 50% 0.2% 1
9 EVANGEL HUYSSEN STIFTUNG 1 50% 0.2% 1
10 GEN SURG SPECIAL SURG TECH 5 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000210908 TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES
2 0.0000193581 PLATINUM RESISTANT//RECURRENT OVARIAN CANCER//PEGYLATED LIPOSOMAL DOXORUBICIN
3 0.0000135858 PLASMA VEGF//MANCHESTER RENAL GRP//PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR
4 0.0000135384 METRONOMIC CHEMOTHERAPY//METRONOMIC//LOW DOSE METRONOMIC CHEMOTHERAPY
5 0.0000114481 FLT 1//VEGF RECEPTORS//VEGF165B
6 0.0000110740 ARID1A//CLEAR CELL CARCINOMA//OVARIAN CLEAR CELL CARCINOMA
7 0.0000099757 ERRMECEEA 1391//GENET MED OBSTET GYNECOL//SCIRRHOUS GASTRIC CARCINOMA
8 0.0000095674 PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS
9 0.0000092423 MICROVESSEL DENSITY//MICROVESSEL COUNT//CHALKLEY
10 0.0000079696 OLAPARIB//SYNTHETIC LETHALITY//PARP INHIBITOR